Recent Advances of PTEN Gene and Immune Escape of Melanoma

doi:10.3969/j.issn.1005-4979.2020.04.012

Abstract

Abstract:

Phosphatase and tensin homolog (PTEN) gene is a powerful tumor suppressor gene on chromosome 10q23.3. It plays an important role in maintaining the balance of cell proliferation, differentiation and apoptosis. The deletion, mutation or inactivation of PTEN is closely related to the occurrence and development of tumors. A large number of studies had shown that the interaction between immune system and the tumor can be changed by PTEN signaling, which leads to immunosuppression and tumor escape. This review aims to summarize the research progress on PTEN gene and immune escape of melanoma.

Key words: phosphatase and tensin homolog (PTEN), immunosuppression, tumor escape

摘要：

磷酸酯酶与张力蛋白同源物（phosphatase and tensin homolog，PTEN）基因是染色体10q23.3上一个强有力的肿瘤抑制基因，在维持细胞的增殖、分化和凋亡平衡中起重要作用。PTEN的缺失、突变或失活与肿瘤的发生、发展关系密切。大量研究表明，PTEN信号改变了免疫系统和肿瘤之间的相互作用，导致免疫抑制和肿瘤逃逸。本文就PTEN基因与黑色素瘤免疫逃逸研究的相关进展作一综述。

关键词: 磷酸酯酶与张力蛋白同源物, 免疫抑制, 肿瘤逃逸

CLC Number:

R782
R739.8

SUN Xu, LI Ning, BAI Bingqing, YANG Yuemei, ZHANG Xudong. Recent Advances of PTEN Gene and Immune Escape of Melanoma[J]. 《Journal of Oral and Maxillofacial Surgery》, 2020, 30(4): 252-255.

孙旭, 李宁, 白冰清, 杨月美, 张旭东. 磷酸酯酶与张力蛋白同源物基因和黑色素瘤的免疫逃逸研究的相关进展[J]. 《口腔颌面外科杂志》, 2020, 30(4): 252-255.

/ / Recommend / Download Citations

URL: https://journal06.magtech.org.cn/Jweb_joms/EN/10.3969/j.issn.1005-4979.2020.04.012

https://journal06.magtech.org.cn/Jweb_joms/EN/Y2020/V30/I4/252

References 24

[1]	Yang S, Liu T, Nan HM, et al. Comprehensive analysis of prognostic immune-related genes in the tumor microenvironment of cutaneous melanoma[J]. J Cell Physiol, 2020, 235(2): 1025-1035. doi: 10.1002/jcp.29018 pmid: 31240705
[2]	Heusinkveld M, de Vos van Steenwijk PJ, Goedemans R, et al. M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4⁺ Th1 cells[J]. J Immunol, 2011, 187(3): 1157-1165. doi: 10.4049/jimmunol.1100889 pmid: 21709158
[3]	Heering J, Erlmann P, Olayioye MA. Simultaneous loss of the DLC1 and PTEN tumor suppressors enhances breast cancer cell migration[J]. Exp Cell Res, 2009, 315(15): 2505-2514. doi: 10.1016/j.yexcr.2009.05.022 pmid: 19482022
[4]	Tseng PC, Huang WC, Chen CL, et al. Regulation of SHP2 by PTEN/AKT/GSK-3β signaling facilitates IFN-γ resistance in hyperproliferating gastric cancer[J]. Immunobiology, 2012, 217(9): 926-934. doi: 10.1016/j.imbio.2012.01.001 URL
[5]	Sanmamed MF, Perez-Gracia JL, Schalper KA, et al. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients[J]. Ann Oncol, 2017, 28(8): 1988-1995. doi: 10.1093/annonc/mdx190 pmid: 28595336
[6]	Mahmoud F, Shields B, Makhoul I, et al. Immune surveillance in melanoma: from immune attack to melanoma escape and even counterattack[J]. Cancer Biol Ther, 2017, 18(7): 451-469. doi: 10.1080/15384047.2017.1323596 pmid: 28513269
[7]	Kogan D, Grabner A, Yanucil C, et al. STAT3-enhancing germline mutations contribute to tumor-extrinsic immune evasion[J]. J Clin Invest, 2018, 128(5): 1867-1872. doi: 10.1172/JCI96708 pmid: 29438108
[8]	Yin D, Li Y, Guo BF, et al. Plasmid-based STAT3 siRNA delivered by functional graphene oxide suppresses mouse malignant melanoma cell growth[J]. Oncol Res, 2016, 23(5): 229-236. doi: 10.3727/096504016X14550280421449 pmid: 27098146
[9]	Rasul A, Ding C, Li XM, et al. Dracorhodin perchlorate inhibits PI3K/Akt and NF-κB activation, up-regulates the expression of p53, and enhances apoptosis[J]. Apoptosis, 2012, 17(10): 1104-1119. doi: 10.1007/s10495-012-0742-1 pmid: 22711363
[10]	Chen CL, Hsieh FC, Lieblein JC, et al. STAT3 activation in human endometrial and cervical cancers[J]. Br J Cancer, 2007, 96(4): 591-599. doi: 10.1038/sj.bjc.6603597
[11]	Hu YS, Han X, Liu XH. STAT3: a potential drug target for tumor and inflammation[J]. Curr Top Med Chem, 2019, 19(15): 1305-1317. doi: 10.2174/1568026619666190620145052 pmid: 31218960
[12]	Dong Y, Richards JA, Gupta R, et al. PTEN functions as a melanoma tumor suppressor by promoting host immune response[J]. Oncogene, 2014, 33(38): 4632-4642. doi: 10.1038/onc.2013.409 pmid: 24141770
[13]	Muenst S, Soysal SD, Tzankov A, et al. The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy[J]. Expert Opin Ther Targets, 2015, 19(2): 201-211. doi: 10.1517/14728222.2014.980235 URL
[14]	Zhang XC, Cao X, Sun C, et al. Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening[J]. Cancer Immunol Immunother, 2018, 67(3): 471-481. doi: 10.1007/s00262-017-2098-4 URL
[15]	Gowrishankar K, Gunatilake D, Gallagher SJ, et al. Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB[J]. PLoS One, 2015, 10(4): e0123410. doi: 10.1371/journal.pone.0123410 URL
[16]	Shabaneh TB, Molodtsov AK, Steinberg SM, et al. Oncogenic BRAFV600E governs regulatory T-cell recruitment during melanoma tumorigenesis[J]. Cancer Res, 2018, 78(17): 5038-5049. doi: 10.1158/0008-5472.CAN-18-0365 pmid: 30026331
[17]	Chapuis AG, Lee SM, Thompson JA, et al. Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient[J]. J Exp Med, 2016, 213(7): 1133-1139. doi: 10.1084/jem.20152021 URL
[18]	王凯波, 刘岩, 金春林, 等. MiR-128对人黑素瘤细胞A375增殖和PTEN及p-Akt蛋白表达的影响[J]. 解剖科学进展, 2017, 23(2): 123-125.
[19]	Müller L, Aigner P, Stoiber D. Type I interferons and natural killer cell regulation in cancer[J]. Front Immunol, 2017, 8: 304. doi: 10.3389/fimmu.2017.00304 pmid: 28408907
[20]	Kalim H, Pratama MZ, Nugraha AS, et al. Regulatory T cells compensation failure cause the dysregulation of immune response in pristane induced lupus mice model[J]. Malays J Med Sci, 2018, 25(3): 17-26.
[21]	Aarreberg LD, Wilkins C, Ramos HJ, et al. Interleukin-1β signaling in dendritic cells induces antiviral interferon responses[J]. mBio, 2018, 9(2): e00318-e00342.
[22]	黄复雪, 李丹丹, 文习之, 等. 中国黏膜黑色素瘤的临床特点及基因突变分析[J]. 中山大学学报(医学版), 2019, 40(2): 244-250.
[23]	Steinberg SM, Turk MJ. BRAF-inhibition and tumor immune suppression[J]. Onco Immunol, 2015, 4(2): e988039.
[24]	Min KW, Choe JY, Kwon MJ, et al. BRAF and NRAS mutations and antitumor immunity in Korean malignant melanomas and their prognostic relevance: gene set enrichment analysis and CIBERSORT analysis[J]. Pathol Res Pract, 2019, 215(12): 152671. doi: 10.1016/j.prp.2019.152671 URL

Please choose a citation manager

Content to export